Semaglutide, tirzepatide, and retatrutide are frequently discussed together because they belong to the same engineered class: peptide-based agonists built around the native incretin hormone GLP-1, modified for extended half-life and, in two of the three, additional receptor targets. Understanding what these compounds have in common structurally — not just which receptors they hit — explains why they've become among the most heavily studied compounds in metabolic peptide research.
Starting point: native GLP-1
Native GLP-1 is a gut-derived hormone with a functional half-life measured in minutes — it's degraded almost immediately by the enzyme DPP-4 and cleared renally. That makes the unmodified hormone impractical as a research tool for anything beyond acute signaling studies. Every major research compound in this class exists specifically to solve that stability problem.
The engineering: fatty-acid acylation
The common solution is to attach a fatty-acid side chain, often via a short linker, to a lysine residue in the peptide backbone. That fatty-acid tail binds reversibly to serum albumin once in circulation, which protects the peptide from enzymatic degradation and substantially extends its functional half-life — a design principle shared, with variations, across the class. Amino-acid substitutions near enzymatic cleavage sites provide additional protection against breakdown.
Compounds studied in this class
- Semaglutide — a selective GLP-1 receptor agonist, and the structural reference point for the class. See its research overview.
- Tirzepatide — engineered to activate both the GIP and GLP-1 receptors, used to study whether dual-receptor engagement produces signaling effects that single-receptor agonism does not. See the tirzepatide overview.
- Retatrutide — a triple agonist adding glucagon receptor activity to the GIP/GLP-1 backbone, studied for effects on energy-expenditure pathways alongside glucose-signaling pathways. See the retatrutide overview.
What researchers use this class to study
In vitro and preclinical models built around this compound class investigate receptor-binding kinetics, downstream cAMP signaling, comparative receptor selectivity, and how multi-receptor agonism differs functionally from single-receptor activation — the same underlying biology covered in more depth in our guide to GLP-1, GIP, and glucagon receptors. Comparative work, such as our semaglutide vs. tirzepatide and retatrutide vs. tirzepatide write-ups, looks at how receptor count maps onto observed differences in research models.
Documentation standard
Every compound in this class is supplied as a lyophilized powder with a batch-specific COA documenting sequence, molecular weight, and measured purity — the same documentation standard that applies across V8 Peptides' catalog regardless of a compound's structural complexity.
A growing, actively studied class
This receptor class hasn't stood still — retatrutide's triple-agonist design is a more recent addition to the field than semaglutide's single-receptor approach, reflecting an ongoing research trajectory toward engaging more of the incretin-hormone family within a single molecule. That progression is part of why the class is worth tracking as a whole rather than compound by compound: each new entrant tends to be studied specifically in relation to the ones that came before it, using the earlier compounds as the comparative baseline for what an additional receptor target changes in a given model.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.